Matthew Gevaert and David Orr developed an innovative approach to cancer research, testing new drug compounds using live cells from patients with a device that resembles a Lego. Gevaert and Orr’s “3DKUBE,” a cell cultured plasticware, creates a 3Dmodel of patient cells that allows researchers to study the growth of the cells in a cultured environment that mimics the conditions of the human body. The process is designed to produce more relevant data on drug safety and efficacy, and determine which drugs are most effective for treating cancer patients. To expand use of this technology, the National Cancer Institute (NCI) awarded a $295,000 Phase 1 Small Business Innovation Research (SBIR) contract to Matthew and David’s company KIYATEC to develop a 3D model specifically for breast cancer patients. The company plans to eventually use the model to more accurately predict a patient’s response to certain drugs for lung and brain cancer.
Just released data from the White House Office of Management and Budget (OMB) details the final amount to be cut from federal research program budgets as sequestration goes into effect. The full details are available on the updated Research!America sequestration fact sheet, though previous projections were relatively accurate as compared to these final numbers.
Cuts to the Centers for Disease Control and Prevention and the Food and Drug Administration will be higher than previously expected, with a combined loss of $593 million dollars for FY13. That amount is roughly equivalent to ensuring the safety of new medical and biological products at the FDA and programs that focus on prevention of HIV/AIDS at CDC. The National Institutes of Health will lose more than $1.5 billion this year alone, enough to fund three major research programs at the National Cancer Institute. The National Science Foundation will lose $290 million, an amount that would almost fully fund the NSF budget for materials research, which includes studies on biomaterials and metallic nanostructures.